Acerus Pharmaceuticals Corporation announced the signing of an agreement granting Maylen Farma the exclusive rights to market NATESTO® in 20 countries across Europe, Central Asia, and the Middle East. Maylen is a privately-owned pharmaceutical company based in Lugano, Switzerland that specializes in bringing innovative pharmaceutical products and healthcare services to patients in emerging markets. Nations covered by the agreement with Acerus include Belarus, Georgia, and Ukraine; Azerbaijan, Uzbekistan, Tajikistan, Kazakhstan, and Kyrgyzstan; Albania, Kosovo, North Macedonia, Serbia, and Bosnia and Herzegovina; the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Jordan, and Lebanon.